Drs. Neil Quigley and Nicholas Potter co-authored a recent article comparing two assays' detection rate of the human papillomavirus (HPV) in women 30 years of age and older.
The objective of the study was to estimate high-risk (HR) HPV prevalence in women negative for intraepithelial lesion or malignancy (NILM) cytology using the Cervista® HPV HR test. The study also compared HR HPV prevalence rates in women and NILM cytology using the Cervista HPV HR and Hybrid Capture® 2 tests. The multi-center study was conducted to analyze HR HPV prevalence rates using the Cervista test from residual ThinPrep® specimens.
According to study results, the HR HPV prevalence rates among women with NILM cytology were not statistically different between the Cervista and Hybrid Capture tests, and the overall percent agreement between the tests was 95.3%. There were no statistically significant differences between tests across age groups or investigational sites. For both tests, there was a statistically significant decrease in HR HPV positive results as age increases.
To identify and differentiate HR HPV types, MPLN offers HPV high risk testing as well as HPV genotyping. For more information about HR HPV and the test available to detect HR HPV, contact a client service specialist at 800.932.2943
No comments yet. Be the first to leave a comment below.